Leflunomide Sandoz (Leflunomide)

Leflunomide is metabolised to teriflunomide, which blocks the enzyme dihydroorotate dehydrogenase. By inhibiting de novo pyrimidine synthesis, the drug limits the proliferation of activated lymphocytes, thereby dampening the autoimmune response that drives joint inflammation.

The dosing regimen for Leflunomide Sandoz is determined by the prescribing clinician based on the individual’s disease severity, renal and hepatic function, and other clinical factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Leflunomide Sandoz is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations. It is also not recommended for breastfeeding mothers because it can be excreted in breast milk and may harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The most common alternative to leflunomide is methotrexate, another DMARD. While both reduce disease activity, leflunomide is taken orally once daily and has a different safety profile, notably a higher risk of liver enzyme elevation and teratogenicity, whereas methotrexate carries risks of mucosal ulceration and pulmonary toxicity.

Leflunomide Sandoz tablets should be stored at temperatures below 25 °C, in their original blister pack or bottle, protected from moisture and direct sunlight. Do not store in bathrooms or near heat sources, and keep out of reach of children.

The medication is supplied as oral tablets that are swallowed whole with water. It can be taken with or without food, but patients should follow any specific instructions from their healthcare provider regarding timing relative to meals.

Serious risks include severe liver injury, life‑threatening skin reactions such as Stevens‑Johnson syndrome, bone‑marrow suppression leading to low blood counts, interstitial lung disease, and teratogenic effects if exposure occurs during pregnancy. Prompt medical attention is required if any of these occur.

Leflunomide Sandoz is contraindicated in pregnant women, women of child‑bearing potential not using effective contraception, patients with severe hepatic impairment, uncontrolled infections, and those with known hypersensitivity to leflunomide or its metabolites.